The Protective Mechanism of CAY10683 on Intestinal Mucosal Barrier in Acute Liver Failure through LPSTLR4MyD88 Pathway

Abstract EN

The purpose of this study was to investigate the protective mechanism of HDAC2 inhibitor CAY10683 on intestinal mucosal barrier in acute liver failure (ALF).

In order to establish ALF-induced intestinal epithelial barrier disruption models, D-galactosamine/LPS and LPS were, respectively, used with rats and NCM460 cell and then administrated with CAY10683.

Transepithelial electrical resistance (TEER) was measured to detect the permeability of cells.

Real-time PCR and Western blotting were employed to detect the key mRNA and protein levels.

The intestinal epithelial tissue pathology was detected.

After interfering with CAY10683, the mRNA and protein levels of TLR4, MyD88, TRIF, and TRAF6 were decreased compared with model group (P<0.05), whereas the levels of ZO-1 and occluding were elevated (P<0.05).

The permeability was elevated in CAY10683-interfered groups, when compared with model group (P<0.05).

And the degree of intestinal epithelial tissue pathological damage in CAY10683 group was significantly reduced.

Moreover, CAY10683 significantly decreased the TLR4 staining in animal tissue.

The HDAC2 inhibitor CAY10683 could promote the damage of intestinal mucosal barrier in ALF through inhibiting LPS/TLR4/MyD88 pathway.